ASLAN Pharmaceuticals announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX. The primary endpoint, which is the percent change in Eczema Area Severity Index (EASI) score from baseline to week 16, was statistically significant when compared to placebo (p=0.0059), even though the interim analysis was not powered for statistical significance due to the sample size. ASLAN announced positive results from the Phase 2b TREK-AD study of eblasakIMab in moderate-to- severe biologic-naive AD patients in July 2023, and is currently investigating eblasakimab In dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.